HomeCompareOTCM vs ABBV

OTCM vs ABBV: Dividend Comparison 2026

OTCM yields 4.84% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OTCM wins by $2759.32M in total portfolio value
10 years
OTCM
OTCM
● Live price
4.84%
Share price
$53.53
Annual div
$2.59
5Y div CAGR
96.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2759.42M
Annual income
$2,637,021,193.96
Full OTCM calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — OTCM vs ABBV

📍 OTCM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOTCMABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OTCM + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OTCM pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OTCM
Annual income on $10K today (after 15% tax)
$411.26/yr
After 10yr DRIP, annual income (after tax)
$2,241,468,014.87/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, OTCM beats the other by $2,241,446,958.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OTCM + ABBV for your $10,000?

OTCM: 50%ABBV: 50%
100% ABBV50/50100% OTCM
Portfolio after 10yr
$1379.76M
Annual income
$1,318,522,982.86/yr
Blended yield
95.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

OTCM
No analyst data
Altman Z
8.9
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OTCM buys
0
ABBV buys
0
No recent congressional trades found for OTCM or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOTCMABBV
Forward yield4.84%3.06%
Annual dividend / share$2.59$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR96.9%40.6%
Portfolio after 10y$2759.42M$102.3K
Annual income after 10y$2,637,021,193.96$24,771.77
Total dividends collected$2750.72M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OTCM vs ABBV ($10,000, DRIP)

YearOTCM PortfolioOTCM Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,653$952.68$11,550$430.00+$103.00OTCM
2$14,511$2,042.85$13,472$627.96+$1.0KOTCM
3$20,208$4,681.40$15,906$926.08+$4.3KOTCM
4$33,620$11,996.82$19,071$1,382.55+$14.5KOTCM
5$72,701$36,727.49$23,302$2,095.81+$49.4KOTCM
6$223,939$146,149.22$29,150$3,237.93+$194.8KOTCM
7$1,068,033$828,418.01$37,536$5,121.41+$1.03MOTCM
8$8,413,330$7,270,534.76$50,079$8,338.38+$8.36MOTCM
9$114,395,236$105,392,972.85$69,753$14,065.80+$114.33MOTCM
10$2,759,424,096$2,637,021,193.96$102,337$24,771.77+$2759.32MOTCM

OTCM vs ABBV: Complete Analysis 2026

OTCMStock

OTC Markets Group Inc. engages in the financial market business in the United States and internationally. It offers OTC Link Alternative Trading System, an interdealer quotation and trade messaging system; OTC Dealer, a real-time, front-end application that provides consolidated quotation, trading, and information system to attract and access market liquidity; OTC FIX, which uses the industry standard FIX protocol for quote submission, trading, and routing of execution reports; and OTC Link Electronic Communication Networks (ECN) and OTC Link National Quotation Bureau (NQB) that acts as the executing party on an agency basis in relation to transactions executed on platforms. The company also provides OTC Markets Real-Time Data products that provides quote, trade, and reference data for OTC Link ATS; OTC Markets Pricing and Reference Data products for detailed view into the securities and issuers within the OTC market; and compliance data products. In addition, it offers OTC Disclosure & News Service for publishing and distributing data, news, and financials; Real-Time Level 2 Quote Display, a service that companies sponsor to provide their investors with access to real-time level 2 quotes on otcmarkets.com and the issuer's Website; Blue Sky Monitoring Service for analysis, review, and guidance about a company's compliance with the United States securities laws; and Virtual Investor Conferences, which allows issuers to communicate and engages with investors, as well as operates the OTCQX Best Market, OTCQB Venture Market, and Pink Open Market. Further, it offers software, and risk and performance analytics tools for the banking and finance industries; online capital raising solutions; and OTCIQ, an investor relations portal. The company was formerly known as Pink OTC Markets Inc. and changed its name to OTC Markets Group Inc. in January 2011. OTC Markets Group Inc. was founded in 1904 and is headquartered in New York, New York.

Full OTCM Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this OTCM vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OTCM vs SCHDOTCM vs JEPIOTCM vs OOTCM vs KOOTCM vs MAINOTCM vs JNJOTCM vs MRKOTCM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.